Wolk Joseph J

CFO Wolk sold 89,654 JNJ shares for $21.8M across 4 transactions on 2026-02-17

Joseph J Wolk, Executive VP and CFO, executed 4 separate sales totaling 89,654 shares for $21,767,826.99 at prices ranging from $242.68 to $242.99, reducing his holdings by 86.5% from 103,654 to 14,000 shares. The blended average sale price of $242.80 is 0.0% from the current 52-week high of $244.99, and the stock is up 12.0% over the prior 30 days and 20.6% over 90 days, indicating the sales occurred near peak valuation. His prior 2 trades at JNJ (both sells in August 2025 and February 2025) showed mixed timing results: the August 2025 sale returned +0.6% in 30 days but +10.4% in 90 days (poorly timed), while the February 2025 sale returned +8.3% in 30 days but +1.2% in 90 days, with 0 of 2 prior JNJ sales well-timed at the 90-day mark. The substantial reduction in stake size alongside the company's robust fundamentals—$24.0B quarterly revenue, $5.2B net income, +6.0% annual growth, and 15.59 P/E—creates tension: this appears to be a significant liquidation near all-time highs rather than a company-confidence signal.

Director Wolk Joseph J bought 400 PRU shares at $105.32 on 2026-02-11; stock now down 12.3% from 52-week high.

Wolk Joseph J, a director, purchased 400 shares of Prudential Financial at $105.32 per share on 2026-02-11, establishing a 400-share position from zero prior holdings. The purchase comes as PRU has declined 12.3% from its 52-week high of $118.72 and is down 10.7% over the past 30 days. Prudential's fundamentals show revenue of $17,888,000,000.00 and net income of $1,431,000,000.00 in the latest quarter, though annual revenue growth is negative at -13.7%, with a P/E of 10.47. The insider's cross-ticker track record shows 2 prior sells with a 90-day well-timed rate of 0.00%, indicating those sales occurred before subsequent gains rather than capturing downturns.

CFO Wolk sold 16.8K JNJ shares at $176.91 for $3.0M, reducing holdings 54.6%, within 0.4% of 52-week high.

Joseph J Wolk, Exec VP and CFO of Johnson & Johnson, sold 16,820 shares at $176.91 on 2025-08-15, reducing his holdings from 30,820 shares to 14,000 shares—a 54.6% reduction in position. The sale price of $176.91 is only 0.2% below the 52-week high of $176.64, placing the transaction near the peak of JNJ's recent range. Over the prior 30 days, JNJ has appreciated 7.7%, and over 90 days, 14.7%, indicating strong momentum at the time of sale. Examining Wolk's prior open-market trades at JNJ, his single prior sale on 2025-02-07 showed a 90-day return of +1.2% to the stock, meaning the stock rose after his sale and he did not benefit from the subsequent gain. This transaction merits investor attention given the insider's senior financial role and the material size of the divestiture occurring near recent highs.

CFO Joseph J Wolk fully exits JNJ position, selling 13,015 shares at $153.89 for $2.0M

Exec VP and CFO Joseph J Wolk liquidated his entire remaining holding of 13,015 shares in Johnson & Johnson on 2025-02-07 at $153.89, netting $2,002,878.35. The complete exit (from 13,015 shares to 0 holdings) represents a material change in his direct equity stake in the company he helps lead financially. Notably, the sale occurred at a price 1.4% below the current market price of $156.13 and near the middle of the 52-week range ($142.06–$167.38), offering no obvious timing extremity. Given his position overseeing JNJ's financials—including recent quarterly results of $22.5B revenue and $2.7B net income, against a backdrop of -10.3% annual revenue decline and a P/E of 25.60—the full liquidation warrants observation of whether similar follow-on transactions emerge or if broader management confidence signals shift.